ADVERTISEMENT
Delix Receives NIDA Grant to Advance Neuroplastogen for SUD
Delix Therapeutics announced that it has been awarded a $320,000 grant from the National Institute on Drug Abuse (NIDA) to support the advancement of its novel neuroplastogen and non-hallucinogenic ibogaine analog, DLX-007.
Currently being evaluated in a range of substance use disorders (SUDs), including opioid and stimulant use, DLX-007 is orally bioavailable, promotes rapid and enduring neuroplasticity, is capable of blood brain barrier penetration, and is suitable for intramuscular administration.
The grant follows research on a Delix compound conducted by NIDA’s Addiction Treatment Discovery Program, which works with industry partners to perform preclinical screening, evaluating novel and promising pharmacotherapies to uncover more effective treatments for the medical management of SUDs.
“We are grateful for NIDA’s continued support of our research platform as we develop non-hallucinogenic neuroplastogens to treat a wide range of disorders, including SUD,” Delix CEO Mark Rus said in a news release. “As the overdose and SUD crises unfortunately continue, rapid acting therapeutics could alter the treatment landscape and address a significant unmet need for patients and their families.
“Public-private partnerships such as our collaboration with NIDA are essential for bringing innovative treatments to more people. The continued growth and development of Delix's neuroplastogen platform will hopefully create the next generation of neuropsychiatric therapies to restore and repair brain function.”
DLX-007 has completed investigational new drug-enabling studies and is slated for clinical testing in 2024.
Reference
